News & Updates

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

In the treatment of individuals with diabetic macular edema, brolucizumab yields similar visual outcomes as aflibercept, according to data from the phase III KINGFISHER trial.

Brolucizumab noninferior to aflibercept for diabetic macular edema

29 Dec 2023

$Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma$

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023 by

In the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), taking ibrutinib and venetoclax together prolongs survival without disease progression, according to the phase III Sympatico study.

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

29 Dec 2023

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

The oral selective tyrosine kinase inhibitor sunvozertinib demonstrates therapeutic potential in patients with nonsmall cell lung cancer (NSCLC) with EGFR exon 20 insertions (exon20ins) who have previously received platinum-based chemotherapy, according to the results of a phase II WU-KONG6 study.

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

29 Dec 2023

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023 by

Treatment with upadacitinib (UPA) delivers clinical benefits to patients with prior Crohn’s disease (CD)-related surgeries, according to a study presented at AIBD 2023. Moreover, a maintenance dose of 30 mg once a day (QD) demonstrates greater efficacy.

Upadacitinib induces CD remission in patients with prior surgery

28 Dec 2023

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023 by

The novel, investigational anti-tissue factor pathway inhibitor marstacimab outdid factor replacement therapy (FRT) in reducing bleeds in patients with severe haemophilia A (HA) or moderately severe to severe haemophilia B (HB) without inhibitors beyond 12 months in the phase III BASIS trial.

Marstacimab trumps FRT for severe haemophilia without inhibitors

28 Dec 2023

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023 by

Risankizumab outdoes ustekinumab in achieving endoscopic remission at week 24 in patients with moderate-to-severe Crohn’s disease (CD), as well as in other clinical, endoscopic, and quality of life (QoL) outcomes, as shown by the results of the phase IIIB SEQUENCE trial presented at AIBD 2023.

Risankizumab superior to ustekinumab in severe CD

27 Dec 2023

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

25 Dec 2023

A 4-week course of racemic ketamine, when given by subcutaneous injection at adequate doses, appears to be safe and efficacious in people with treatment-resistant depression, according to a phase III trial.

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

25 Dec 2023

Remdesivir shows no clear benefit in children with severe COVID-19

25 Dec 2023 by

The antiviral remdesivir offers no clear benefit in the treatment of children with severe COVID-19, falling short of reducing the time spent in high dependency or intensive care unit (HD/ICU), according to a study from Singapore.

Remdesivir shows no clear benefit in children with severe COVID-19

25 Dec 2023

$Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis$

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

24 Dec 2023 by

Fedratinib is superior to the best available therapy (BAT) in terms of spleen volume reduction (SVR) and symptom response rates in patients with myelofibrosis (MF) treated with the Janus kinase inhibitor (JAKi) ruxolitinib, as shown in a study presented at ASH 2023.

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

24 Dec 2023

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

Treatment with metformin plus insulin early in pregnancy for women with pre-existing type 2 diabetes (T2D) or gestational diabetes falls short of reducing the risk of adverse neonatal outcomes, as shown in the MOMPOD study.

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

23 Dec 2023

News & Updates

Filter by Specialty:

Specialty:

Brolucizumab noninferior to aflibercept for diabetic macular edema

Brolucizumab noninferior to aflibercept for diabetic macular edema

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Ibrutinib plus venetoclax yields survival gains in relapsed/refractory mantle cell lymphoma

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Sunvozertinib shows promise in pretreated NSCLC with EGFR exon 20 insertions

Upadacitinib induces CD remission in patients with prior surgery

Upadacitinib induces CD remission in patients with prior surgery

Marstacimab trumps FRT for severe haemophilia without inhibitors

Marstacimab trumps FRT for severe haemophilia without inhibitors

Risankizumab superior to ustekinumab in severe CD

Risankizumab superior to ustekinumab in severe CD

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

Adequately dosed racemic ketamine shots beneficial in treatment-resistant depression

Remdesivir shows no clear benefit in children with severe COVID-19

Remdesivir shows no clear benefit in children with severe COVID-19

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

Fedratinib is best therapy for ruxolitinib-refractory myelofibrosis

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes

Metformin plus insulin for T2D, gestational diabetes does little to improve neonatal outcomes